seoulpharma

Market position

A KOSDAQ-listed Korean generic and specialty pharmaceutical manufacturer differentiated by patented ODF formulation technology, with supply relationships with multinational firms including Pfizer and Sandoz.

Patented and commercialized ODF/Smart Film oral thin-film formulations, developed over an extended R&D period, allow the company to license and supply film versions of established molecules to partners in multiple territories rather than competing solely on conventional generics.

Technology

The core platform is orally disintegrating film (ODF), marketed as Smart Film, a thin oral film dosage form presented as an alternative to orally disintegrating tablets. Approved and commercialized ODF products include sildenafil citrate, tadalafil, donepezil and aripiprazole films. Manufacturing is conducted at a cGMP-grade plant in the Osong Bio-medical Complex holding PIC/S GMP approval from the MFDS, with earlier KGMP approval from the KFDA.

Go-to-market

Combination of an established domestic sales platform in Korea and exclusive territory supply agreements with overseas partners, including Pfizer (Korea), Sandoz AG (East Asia), GHC (China), SOHO (Indonesia), SAJA (8 GCC countries) and DISTOLOZA (Peru).

Domestic Korean pharmaceutical distribution channels and healthcare professionals, plus international pharmaceutical partners licensing or distributing ODF products in Asia, the Middle East and Latin America.

Geography

Headquartered in Seoul (325 Hakdong-ro, Gangnam-gu), with a manufacturing plant in the Osong Bio-medical Complex in Cheongju, Chungcheongbuk-do, and an R&D center in Anyang-si, Gyeonggi-do; earlier records list a plant in the Sihwa Industrial Park, Siheung, Gyeonggi-do. Products are distributed domestically and exported to China, Indonesia, GCC countries, Peru and East Asian markets.

History

Founded in August 1976 as Seoul New Drug Industry, the business was incorporated as Seoul Pharma Co., Ltd. in December 1985. It received KGMP approval from the KFDA in November 1992, expanded and relocated its plant to the Sihwa Industrial Complex in Siheung, Gyeonggi-do in October 1996, and founded its R&D center in February 1997. It listed on the KOSDAQ in August 2000 and in August 2006 reported development of molecular target RhoB for a first-in-class oncology drug. A Fair Trade Compliance Program was introduced in April 2008. Sildenafil citrate ODF was approved as Smart Film technology in May 2012, followed by an exclusive Korean supply agreement with Pfizer in November 2012 and the Korea New Drug Development Award for technology export in February 2013. Construction of a new cGMP factory in the Osong Bio-medical Complex was completed in March 2013 and the plant received PIC/S GMP approval from the MFDS in May 2015. Subsequent supply agreements covered Sandoz AG (2016), GHC in China (2017), SOHO in Indonesia (2017), SAJA in the GCC (2017) and DISTOLOZA in Peru (2018).